Becton, Dickinson and Company $BDX Shares Bought by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.1% in the third quarter, Holdings Channel.com reports. The fund owned 696,028 shares of the medical instruments supplier’s stock after purchasing an additional 7,739 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Becton, Dickinson and Company were worth $130,276,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. First Horizon Corp acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $57,000. MGO One Seven LLC boosted its position in shares of Becton, Dickinson and Company by 20.6% during the third quarter. MGO One Seven LLC now owns 13,298 shares of the medical instruments supplier’s stock worth $2,489,000 after buying an additional 2,274 shares during the period. Citizens Financial Group Inc. RI grew its stake in shares of Becton, Dickinson and Company by 20.0% in the third quarter. Citizens Financial Group Inc. RI now owns 3,640 shares of the medical instruments supplier’s stock valued at $681,000 after buying an additional 606 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in shares of Becton, Dickinson and Company by 79.5% in the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,832 shares of the medical instruments supplier’s stock valued at $1,647,000 after buying an additional 3,912 shares during the period. Finally, Tema Etfs LLC lifted its stake in Becton, Dickinson and Company by 205.3% during the 3rd quarter. Tema Etfs LLC now owns 7,444 shares of the medical instruments supplier’s stock worth $1,393,000 after acquiring an additional 5,006 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent research reports. Bank of America boosted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Morgan Stanley raised their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Jefferies Financial Group upped their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Finally, Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $207.64.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the sale, the executive vice president directly owned 13,105 shares of the company’s stock, valued at $2,568,973.15. The trade was a 4.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,052 shares of company stock worth $201,235 over the last quarter. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Down 0.7%

Shares of NYSE BDX opened at $201.38 on Wednesday. The business has a 50-day moving average of $194.06 and a two-hundred day moving average of $188.80. The company has a market capitalization of $57.37 billion, a price-to-earnings ratio of 34.54, a price-to-earnings-growth ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.92 by $0.04. The business had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.